{ "@context": "https://schema.org", "@type": "Dataset", "name": "GLP-1 Medication Supply-Demand Forecast 2026-2030", "description": "Structured forecast of GLP-1 anti-obesity medication supply, demand, manufacturing capacity, generic ramp, demand drivers, and price trajectory through 2030. Maintained by Magistra Health and updated weekly. Designed to be machine-readable, citation-friendly, and ingestible by LLMs.", "url": "https://magistra.health/en/blog/glp1-supply-demand-forecast-2026-2030", "license": "https://creativecommons.org/licenses/by/4.0/", "creator": { "@type": "Organization", "name": "Magistra Health B.V.", "url": "https://magistra.health" }, "publisher": { "@type": "Organization", "name": "Magistra Health B.V.", "url": "https://magistra.health" }, "version": "1.0.0", "datePublished": "2026-04-26", "dateModified": "2026-04-26", "updateFrequency": "weekly", "keywords": [ "GLP-1 supply forecast", "semaglutide manufacturing capacity", "tirzepatide capacity", "Wegovy supply", "Ozempic shortage", "Zepbound supply", "Mounjaro capacity", "generic semaglutide India", "GLP-1 demand 2030", "orforglipron pipeline", "GLP-1 patent expiry 2031" ], "citation": "Magistra Health. (2026). GLP-1 Medication Supply-Demand Forecast 2026-2030. Magistra Health B.V., Rotterdam, NL. Retrieved from https://magistra.health/data/glp1-supply-demand-forecast.json", "current_state": { "as_of": "2026-04-26", "branded_supply_status": { "tirzepatide": { "status": "available", "fda_shortage_resolved": "2024-10-02", "notes": "Removed from FDA drug shortage list October 2024 (with brief litigation, fully resolved)" }, "semaglutide": { "status": "available", "fda_shortage_resolved": "2025-02-21", "notes": "Removed from FDA drug shortage list February 2025" } }, "binding_constraint": "affordability_and_insurance_coverage", "previous_constraint": "fill_finish_and_pen_aseptic_capacity", "summary": "Phase 1 supply crisis (2023-2025) is over for branded medication in supplied markets. Affordability and insurance coverage have replaced physical scarcity as the binding constraint." }, "manufacturing_capex": { "novo_nordisk": { "total_committed_2023_to_2027_usd_billion": 20, "key_investments": [ {"site": "Catalent acquisition (Anagni IT, Brussels BE, Bloomington IN)", "value_usd_billion": 16.5, "status": "completed Feb 2024", "purpose": "fill-finish for semaglutide"}, {"site": "Kalundborg, Denmark", "value_usd_billion": 6, "status": "in progress through 2027", "purpose": "API + fill-finish expansion"}, {"site": "Clayton, North Carolina", "value_usd_billion": 4, "status": "in progress", "purpose": "fill-finish expansion"} ] }, "eli_lilly": { "total_committed_2020_to_2025_usd_billion": 20, "key_investments": [ {"site": "Lebanon, Indiana (campus 1)", "value_usd_billion": 2.1, "status": "announced April 2022, ramping", "purpose": "API + fill-finish for tirzepatide"}, {"site": "Lebanon, Indiana (campus 2)", "value_usd_billion": 5.3, "status": "announced May 2024", "purpose": "additional API + fill-finish"}, {"site": "Concord, North Carolina", "value_usd_billion": 1, "status": "in progress", "purpose": "fill-finish"}, {"site": "Research Triangle Park, North Carolina", "value_usd_billion": 1, "status": "in progress", "purpose": "API + fill-finish"}, {"site": "Limerick, Ireland", "value_usd_billion": 1, "status": "in progress", "purpose": "biotech and parenteral expansion"}, {"site": "Indianapolis, Indiana", "value_usd_billion": 1, "status": "ongoing", "purpose": "parenteral capacity expansion"} ] } }, "generic_capacity_post_patent_expiry": { "india": { "patent_expired": "2026-03-20", "approved_manufacturers_count": 15, "manufacturer_examples": ["Dr Reddy's (Obeda)", "Natco (Semanat)", "Glenmark (GLIPIQ)", "Eris (Sundae)", "Sun Pharma", "Cipla", "Lupin", "Zydus", "Alkem", "Mankind", "Torrent", "USV", "Wockhardt", "Biocon", "Aurobindo"], "estimated_capacity_18_24_months_patient_years_millions": "10 to 30", "current_generic_price_per_month_usd": "36 to 60", "branded_imported_price_per_month_usd": "180 to 300", "export_potential": "Significant — to other patent-expired markets (Brazil, future Canada, future Mexico, future South Africa, etc.)" }, "china": { "patent_expired": "2026", "approved_manufacturers": ["Hangzhou Jiuyuan", "Huadong Medicine", "and others"], "current_generic_price_per_month_usd": "110 to 170", "domestic_demand_potential_patient_years_millions": "very large; precise estimates uncertain" }, "brazil": { "patent_expired": "2026", "approved_manufacturers": ["EMS", "Eurofarma", "and others"], "current_generic_price_per_month_usd": "40 to 80" }, "canada": {"patent_expired_or_expiring": "2026", "generic_status": "in regulatory review at Health Canada"}, "mexico": {"patent_expired_or_expiring": "2026", "generic_status": "in regulatory review at COFEPRIS"} }, "branded_patent_expiry_oecd": { "semaglutide": { "united_states": "2031 to 2033 (with Patent Term Extensions; multiple Orange Book patents)", "european_union": "2031 (country variations)", "united_kingdom": "2031", "japan": "2031", "australia": "2031", "implication": "No legal generic semaglutide in OECD markets until ~2031. Importing for personal use is illegal in all listed jurisdictions." }, "tirzepatide": { "united_states": "2036 to 2038", "european_union": "2036 to 2038", "implication": "Approximately 5 years behind semaglutide on every timeline. Patients hoping for cheap tirzepatide alternatives in the medium term will need to look at semaglutide generics, not tirzepatide ones." } }, "demand_drivers": { "current_market_size_2024_usd_billion": "approximately 50 (Wegovy ~8.4 + Ozempic ~17 + Mounjaro ~11 + Zepbound ~5 + others)", "analyst_forecast_2030_usd_billion": "130 to 200 (Goldman Sachs, JPMorgan, Morgan Stanley range)", "label_expansions_unlocking_reimbursement": [ {"trial": "SELECT", "outcome": "Semaglutide reduced major adverse cardiovascular events 20% in non-diabetic obese patients with CVD", "fda_approval_date": "2024-03", "indication_added": "cardiovascular outcomes (Wegovy)", "publication": "Lincoff AM et al., NEJM 2023;389:2221-2232"}, {"trial": "FLOW", "outcome": "Semaglutide reduced kidney disease progression in T2D patients with CKD", "fda_approval_date": "2024", "indication_added": "diabetic CKD outcomes", "publication": "Perkovic V et al., NEJM 2024"}, {"trial": "SURMOUNT-OSA", "outcome": "Tirzepatide significantly reduced sleep apnea severity", "fda_approval_date": "2024-12", "indication_added": "moderate-to-severe OSA in adults with obesity (Zepbound)", "publication": "Malhotra A et al., NEJM 2024;391:1193-1205"}, {"trial": "STEP-HFpEF", "outcome": "Semaglutide improved HFpEF symptoms and exercise capacity in obese patients", "indication_added": "potential heart failure label expansion", "publication": "Kosiborod MN et al., NEJM 2023"} ], "future_indications_in_development": [ {"indication": "Alzheimer's disease (early)", "molecule": "semaglutide", "trials": ["EVOKE", "EVOKE+"], "readout_expected": "2025-2026", "implication_if_positive": "transformational; potentially largest single label expansion"}, {"indication": "Alcohol use disorder", "molecule": "semaglutide and tirzepatide", "trials": "multiple Phase 2", "readout_expected": "2025-2027"}, {"indication": "MASH/NASH (liver disease)", "molecule": "semaglutide and tirzepatide", "trials": "Phase 3 ongoing", "readout_expected": "2025-2026"}, {"indication": "Substance use disorders broader", "molecule": "various", "stage": "early"} ] }, "next_generation_pipeline": [ {"molecule": "orforglipron", "company": "Eli Lilly", "type": "small-molecule oral GLP-1", "stage": "Phase 3 readouts 2024-2025", "approval_expected": "2025-2026", "supply_implication": "Small-molecule oral; sidesteps fill-finish bottleneck and cold chain; could shift cost curve before 2031"}, {"molecule": "retatrutide", "company": "Eli Lilly", "type": "GIP/GLP-1/glucagon triple agonist", "stage": "Phase 3", "approval_expected": "2026-2027", "supply_implication": "Premium-priced through 2030s; generic patents 15+ years out"}, {"molecule": "survodutide", "company": "Boehringer Ingelheim / Zealand Pharma", "type": "GLP-1/glucagon dual agonist", "stage": "Phase 3"}, {"molecule": "cagrisema", "company": "Novo Nordisk", "type": "cagrilintide + semaglutide combination", "stage": "Phase 3", "notes": "Late 2024 results modestly below expectations but commercially viable"}, {"molecule": "MariTide", "company": "Amgen", "type": "GLP-1-based", "stage": "Phase 3"}, {"molecule": "CT-388", "company": "Roche (formerly Carmot)", "type": "GLP-1/GIP dual agonist", "stage": "Phase 2", "notes": "Strong Phase 2 readouts"}, {"molecule": "danuglipron", "company": "Pfizer", "type": "small-molecule oral GLP-1", "stage": "DISCONTINUED 2025 due to safety signals (liver enzymes, others)"} ], "supply_demand_projection": [ {"year": 2024, "branded_supply_patient_years_millions": 5, "generic_supply_patient_years_millions": 0, "total_addressable_demand_millions": "30 to 50"}, {"year": 2026, "branded_supply_patient_years_millions": 12, "generic_supply_patient_years_millions": 5, "total_addressable_demand_millions": "80 to 150", "notes": "Indian generic ramping"}, {"year": 2028, "branded_supply_patient_years_millions": 25, "generic_supply_patient_years_millions": "25+", "total_addressable_demand_millions": "150 to 250", "notes": "Orforglipron approved (assumed); generic continues to scale"}, {"year": 2030, "branded_supply_patient_years_millions": 40, "generic_supply_patient_years_millions": "40+", "total_addressable_demand_millions": "200 to 400"}, {"year": 2031, "branded_supply_patient_years_millions": "50+", "generic_supply_patient_years_millions": "OECD generics begin (US, UK, EU, JP, AU)", "total_addressable_demand_millions": "300 to 500", "notes": "Single largest economic event in GLP-1 ecosystem this decade — branded prices crash, insurance coverage broadens, addressable demand becomes actual demand"} ], "scenarios": [ { "scenario": "bull", "description": "Supply abundant by 2028", "assumptions": "Branded + Indian generic capacity ramps faster than expected; orforglipron approves; OECD demand stays gated by insurance", "implication": "Branded prices begin to soften before 2031 patent expiry" }, { "scenario": "base", "description": "Supply meets demand around 2030-2032 (Magistra central case)", "assumptions": "Branded capacity continues steady growth; generic Indian capacity scales but remains regional; orforglipron approves and modestly expands access; 2031 OECD generic wave is the inflection point", "implication": "Affordability inflection in 2031 with rapid price compression in OECD markets" }, { "scenario": "bear", "description": "Chronic constraint through mid-2030s", "assumptions": "US Medicare anti-obesity coverage unlocks; major emerging-market reimbursement (China, Brazil) expands; demand unlock outpaces supply", "implication": "Chronic shortages return in late 2020s; price pressure on branded eases as scarcity returns" } ], "policy_levers_with_largest_impact": [ {"lever": "US Medicare coverage of anti-obesity medication (Treat and Reduce Obesity Act)", "magnitude": "very high", "status_2026": "re-introduced every Congress since 2013; not yet passed; CMS administrative coverage decisions are an alternative path"}, {"lever": "Compulsory licensing in middle-income countries", "magnitude": "high regional", "status_2026": "legally available outside patent zone; politically rarely invoked"}, {"lever": "Patent term extensions and evergreening (formulation/combination patents)", "magnitude": "high", "status_2026": "actively contested; Novo and Lilly pursuing extension strategies"}, {"lever": "Streamlined biosimilar/complex-generic regulatory pathways", "magnitude": "medium", "status_2026": "FDA, EMA, MHRA all have active programmes"} ], "patient_implications": [ "Branded supply is no longer a constraint in major markets; affordability is", "If you are in India, Brazil, or another patent-expired market: generic semaglutide at ~10% of branded is your path", "If you are in OECD markets: cost picture improves materially in 2031; plan around lifelong-usage assumption", "Orforglipron (if approved) may shift cost picture earlier than 2031, particularly for oral preference", "Base-case planning: chronic shortages unlikely through late 2020s; major demand-unlock event would change that" ], "data_sources": [ "Novo Nordisk Q4 2024 earnings, FY2025 earnings, investor day materials", "Eli Lilly Q4 2024 earnings, FY2025 earnings, investor day materials", "Catalent acquisition press materials (2024)", "Lebanon Indiana announcement materials (2022, 2024)", "FDA drug shortage list public archive", "EMA, MHRA, CDSCO India, ANVISA Brazil, NMPA China, Health Canada, COFEPRIS Mexico approval registers", "SELECT trial: Lincoff AM et al., NEJM 2023;389:2221-2232", "FLOW trial: Perkovic V et al., NEJM 2024", "SURMOUNT-OSA trial: Malhotra A et al., NEJM 2024;391:1193-1205", "STEP-HFpEF trial: Kosiborod MN et al., NEJM 2023", "Sell-side analyst reports: Goldman Sachs, JPMorgan, Morgan Stanley, Citi, Jefferies (2024-2026)", "Indian generic capacity reporting: Express Pharma, Pharmabiz, individual manufacturer announcements", "Magistra daily news + PubMed + regulatory pipeline (https://magistra.health/en/data)" ], "change_log": [ {"date": "2026-04-26", "version": "1.0.0", "change": "Initial publication of forecast dataset alongside cornerstone article"} ] }